Please provide your email address to receive an email when new articles are posted on . BOSTON — Poor phase-2 and phase-3 trial results prompted Merck to discontinue development of vicriviroc, a CCR-5 ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
Merck's phase III studies of vicriviroc fails to meet primary endpoints in HIV infected patients ...
Schering-Plough Corporation reported long-term data with vicriviroc, its investigational extracellular inhibitor of HIV infection, from a Phase 2 study in treatment-experienced HIV-infected patients.
July 24, 2007 (Sydney) — The experimental CCR5 inhibitor vicriviroc appears to potently suppress HIV-1 RNA for 48 weeks in treatment-experienced patients, according to a report from a phase 2 trial — ...
Vicriviroc is a next-generation HIV entry inhibitor designed to prevent the virus from infecting CD4 cells by blocking its predominant entry route, the CCR5 co-receptor. Approximately 80-90 percent of ...
Merck has reported initial pooled results from two Phase III studies of vicriviroc, its investigational HIV CCR5 receptor antagonist, in treatment-experienced HIV-infected patients, and said that ...
BOSTON, Feb. 6 Schering-Plough Corporation(NYSE: SGP) today reported that final results of a Phase II clinical studyshowed vicriviroc, its investigational CCR5 antagonist, demonstrated potentand ...
February 5, 2008 (Boston) — The CCR5 antagonist vicriviroc (VCV), in a regimen containing a protease inhibitor boosted with low-dose ritonavir (RTV), has demonstrated potent activity against HIV in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results